Oncology Translational Research, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA, USA. Connie L
Leuk Res. 2010 Sep;34(9):1224-31. doi: 10.1016/j.leukres.2010.02.005. Epub 2010 Mar 3.
Leukemia cell lines were treated with eltrombopag or thrombopoietin and their proliferative response was determined. Eltrombopag did not increase proliferation of cell lines that did not express high levels of megakaryocyte markers. Instead, treatment with eltrombopag alone inhibited proliferation of many cell lines (IC(50) range=0.56-21 microg/mL). The addition of other cytokines, such as G-CSF, Epo or Tpo, did not affect the decrease in proliferation. The decrease in proliferation appears to be through a TpoR-independent, nonapoptotic mechanism. These findings suggest that eltrombopag does not enhance, but rather inhibits, proliferation of leukemia cell lines in vitro.
用艾曲波帕或血小板生成素处理白血病细胞系，并测定其增殖反应。艾曲波帕不会增加不表达高水平巨核细胞标志物的细胞系的增殖。相反，艾曲波帕单独治疗抑制了许多细胞系的增殖（IC50 范围=0.56-21μg/ml）。添加其他细胞因子，如 G-CSF、Epo 或 Tpo，并不影响增殖的减少。增殖的减少似乎是通过 TpoR 非依赖、非凋亡机制实现的。这些发现表明，艾曲波帕不会增强，而是抑制体外白血病细胞系的增殖。
